Clinical trials: STDs
HIV/AIDS
PeerNaija: A Mobile Health Platform Incentivizing Medication Adherence Among Youth Living With HIV in Nigeria
The PEERNaija application will feature routine medication reminders, along with individual adherence monitoring with adherence scores, anonymized peer adherence scores (from peers attending the same clinic; social incentive), and…
- Trial name
- NCT04930198
- Testing
- PeerNaija
- Where
- 2 sites in Nigeria
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
HIV Infections
A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM
The proposed MyPEEPS Mobile intervention is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information specifically developed for at-risk young men who have sex with men (YMSM).
- Trial name
- NCT03167606
- Testing
- MyPEEPS Mobile
- Where
- 4 sites in United States
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Infections
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants.
- Trial name
- NCT00112047
- Testing
- Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV)
- Where
- 5 sites in United States
- Volunteers
- 517 people
- Sponsor
- Gilead Sciences
Acquired Immunodeficiency Syndrome
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval, following administration to male and female HIV-negative healthy volunteers of: 1.
- Trial name
- ENCORE3 (NCT00985543)
- Testing
- lopinavir/ritonavir
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV/AIDS, Alcohol Abuse
Couple-Based Motivational Interviewing With Mobile Breathalyzers to Reduce Alcohol Use in South Africa
This project aims to develop and pilot test an intervention using couple-based motivational interviewing (MI) and mobile breathalyzers to reduce heavy alcohol use with couples living with HIV in South Africa.
- Trial name
- NCT05756790
- Testing
- Motivational Interviewing, Motivational Interviewing plus Breathalyzer
- Where
- South Africa
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Infections, Smoking Cessation
BAPS in Botswana: The Thotloetso Trial
The main purpose of this research study is to compare traditional behavioral smoking cessation therapy with a different type of behavioral therapy-known as behavioral activation problem solving (BAPS)-for smoking cessation.
- Conditions
- HIV Infections, Smoking Cessation, Smoking
- Trial name
- BOTS (NCT04532970)
- Testing
- Cessation Counseling
- Where
- Botswana
- Volunteers
- 651 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Infection, Human Immunodeficiency Virus, HIV Infections
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
HIV/Tuberculosis (TB) co-infection have profound effects on the host's immune system. TB is the most common cause of death in patients with HIV worldwide.
- Trial name
- NCT02178592
- Testing
- DTG 50 mg, EFV 600 mg
- Where
- 28 sites in Argentina, Brazil and 5 more
- Volunteers
- 113 people
- Sponsor
- ViiV Healthcare
Opioid Use Disorder, HIV Infections
Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington
The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle.
- Conditions
- Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea
- Trial name
- NCT06187064
- Testing
- Mobile Van Clinic
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV/AIDS
Social Media HIV Prevention Intervention for High Risk Rural Women
The overall aim of this R34 application is to adapt and feasibility test an evidence-based HIV prevention education for high-risk, underserved rural women in Appalachia.
- Trial name
- NCT03456453
- Testing
- NIDA Standard for HIV Prevention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Michele Staton
HIV-1
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MERIT (NCT00098293)
- Testing
- Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
- Where
- 144 sites in United States, Argentina and 12 more
- Volunteers
- 916 people
- Sponsor
- ViiV Healthcare
HIV/AIDS, Adherence, Medication
Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor
Truvada®, an oral pill comprised of two anti-retroviral compounds, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), is currently the only drug combination approved for pre-exposure prophylaxis (PrEP) in women exposed…
- Conditions
- HIV/AIDS, Adherence, Medication, Drug Use
- Trial name
- NCT04870671
- Testing
- Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Eastern Virginia Medical School
Pharyngeal Gonococcal Infection
Gent for Pharyngeal Gonorrhea (GC)
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats.
- Trial name
- NCT03632109
- Testing
- gentamicin 360mg IM
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
HIV Infection
Traditional Healer-initiated HIV Counseling and Testing in South Africa
The objective of this proposal is to conduct a pilot test of a program aimed at training traditional healers to conduct HIV testing and implementing HIV testing among people living in Bushbuckridge, South Africa.
- Trial name
- NCT05079347
- Testing
- HIV rapid test
- Where
- South Africa
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Human Immunodeficiency Virus
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at…
- Trial name
- NCT04250636
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Rockefeller University
HIV Infections
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
This is an open-label, single-center, single group, non-randomized, two-period, single sequence, mass balance study which will enroll 6 healthy male participants.
- Trial name
- NCT04507321
- Testing
- GSK3640254 Oral tablet, [14C]-GSK3640254 intravenous infusion, [14C]-GSK3640254 powder
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Tuberculosis
Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
The investigators propose to conduct a phase 2 randomised (1:1) double-blind placebo-controlled trial of the dolutegravir-lamivudine-tenofovir fixed dose combination tablet daily with an additional 50 mg dose of…
- Trial name
- RADIANT-TB (NCT03851588)
- Testing
- Dolutegravir 50 mg
- Where
- South Africa
- Volunteers
- 108 people
- Sponsor
- University of Cape Town
Human Immunodeficiency Virus
A Single Dose of Pembrolizumab in HIV-Infected People
Background: Human immunodeficiency virus (HIV) attacks the immune system. Some people with HIV have a low CD4+ T-cell count despite taking antiviral medicines that control HIV replication.
- Trial name
- NCT03367754
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Facial Lipoatrophy
Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment…
- Trial name
- NCT02342223
- Testing
- Voluma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jared Jagdeo, MD, MS
HIV, HIV Infections
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in…
- Trial name
- EYEWITNESS (NCT05911360)
- Testing
- DTG/3TC
- Where
- 56 sites in United States, Austria and 10 more
- Volunteers
- 205 people
- Sponsor
- ViiV Healthcare